Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: A prospective, controlled, blinded, and randomized study

Journal of Veterinary Internal Medicine

Volumn 21, Issue 4, 2007, Pages 742-753

  Chetboul, Valérie ^a,b,c   Lefebvre, Hervé P ^c,d   Sampedrano, Carolina Carlos ^a   Gouni, Vassiliki ^a   Saponaro, Vittorio ^a   Serres, François ^a   Concordet, Didier ^c,d   Nicolle, Audrey P ^a   Pouchelon, Jean Louis ^a,b  

^a Unité de Cardiologie d'Alfort   (France)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^d CNRS   (France)

Author keywords

Angiotensin converting enzyme inhibitor; Inotrope; Phosphodiesterase III inhibitor

Indexed keywords

BENAZEPRIL; BENZAZEPINE DERIVATIVE; PIMOBENDAN; PYRIDAZINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART MUSCLE; MITRAL VALVE REGURGITATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ANIMALS; BENZAZEPINES; BLOOD PRESSURE; BODY WEIGHT; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; MITRAL VALVE INSUFFICIENCY; MYOCARDIUM; PYRIDAZINES; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 34547800235     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[742:CACEOP]2.0.CO;2     Document Type: Article

References (35)

1. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the Cooperative Veterinary Enalapril Study Group. J Vet Intern Med 1995;9:243-252.
2. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998;213:1573-1577.
3. Pouchelon JL, Martignoni L, King JN, et al. The BENCH Study Group. The effect of Benazepril on survival times and clinical signs of dogs with congestive heat failure: Results of a multicenter, prospective, randomised, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:7-18.
4. Pouchelon JL, King JN, Martignoni L, et al. Long-term tolerability of benazepril in dogs with congestive heart failure. J Vet Cardiol 2004;6:7-13.
5. Amberger C, Chetboul V, Bomassi E, et al. Comparison of the effects of imidapril and enalapril in a prospective multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol 2004;6:9-16.
6. Kvart C, Häggström J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
7. Lee JA, Ruegg JC, Allen DG. Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle. Clin Sci 1989;76:609-618.
8. Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002;16:255-261.
9. Fuentes VL. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract 2004;34:1145-1155.
10. Smith PJ, French AT, Van Israel N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121-130.
11. Schneider P, Guttner J, Eckenfels A, et al. Comparative cardiac toxicity of the I.V. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs. Exp Toxicol Pathol 1997;49:217-224.
12. Tissier R, Chetboul V, Moraillon R, et al. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovasc Toxicol 2005;5:43-51.
13. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure, Cochrane Database Syst Rev 2005;25:1.
14. FDA Good Clinical Practice, VICH GL9. Guidance for Industry 85, May 9, 2001. Center for Veterinary Medicine, Food and Drug Administration, US Department of Health and Human Services, Washington, DC. Available at: http://www.fda.gov/cvm/ guidance.
15. Boon JA. Echocardiographic reference values. In: Manual of Veterinary Echocardiography. Baltimore, MD: Lippincott Williams & Wilkins; 1998:453-473.
16. Chetboul V, Carlos Sampedrano C, Concordet D, et al. Use of quantitative two-dimensional color tissue Doppler imaging for assessment of left ventricular radial and longitudinal myocardial velocities in dogs. Am J Vet Res 2005;66:953-961.
17. Stepien RL, Rapoport GS, Henik RA, et al. Comparative diagnostic test characteristics of oscillometric and Doppler
18. ultrasonographic methods in the detection of systolic hypertension in dogs. J Vet Intern Med 2003;17:65-72.
19. Watson AD, Lefebvre HP, Concordet D, et al. Plasma exogenous creatinine clearance test in dogs: Comparison with other methods and proposed limited sampling strategy. J Vet Intern Med 2002;16:22-33.
20. Chetboul V, Athanassiadis N, Concordet D, et al. Observerdependent variability of quantitative clinical endpoints: The example of canine echocardiography. J Vet Pharmacol Ther 2004;27:49-56.
21. Chetboul V, Athanassiadis N, Carlos Sampedrano C, et al. Assessment of repeatability, reproducibility, and effect of anesthesia on determination of radial and longitudinal left ventricular velocities via tissue Doppler imaging in dogs. Am J Vet Res 2004;65:909-915.
22. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
23. Muzzi RAL, de Araújo RB, Muzzi LAL, et al. Regurgitant jet area by Doppler color flow mapping: quantitative assessment of mitral regurgitation severity in dogs. J Vet Cardiol 2003;5:33-38.
24. Kittleson MD, Brown WA. Regurgitant fraction measured by using the proximal isovelocity surface area method in dogs with chronic myxomatous mitral valve disease. J Vet Intern Med 2003;17:84-88.
25. Hanton G, Gautier M, Bonnet P, et al. Effect of milrinone on echocardiographic parameters after single dose in Beagle dogs and relationship with drug-induced cardiotoxicity. Toxicol Lett 2005;155:307-317.
26. Hanton G, Gautier M, Bonnet P. Using M-mode and Doppler echocardiography to investigate the cardiotoxicity of minoxidil in Beagle dogs. Arch Toxicol 2004;78:40-48.
27. Hanai K, Takaba K, Manabe S, et al. Evaluation of cardiac function by echocardiography in dogs treated with doxorubicin. J Toxicol Sci 1996;21:1-10.
28. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in evaluation of left ventricular diastolic function, J Am Coll Cardiol 1997;30:474-480.
29. Shimizu Y, Uematsu M, Nagaya N, et al. Myocardial velocity gradient reflects the severity of myocardial damage regardless of the presence or absence of mitral regurgitation. J Am Soc Echocardiogr 2003;16:246-253.
30. Schneider P, Bauer M, Eckenfelds A, et al. Acute, subacute and chronic toxicity studies of pimobendan in laboratory animals. Pharmacometrics 1992;42:561-578.
31. Vatner DE, Homcy CJ, Sit SP, et al. Effects of pressure overload, left ventricular hypertrophy on beta-adrenergic receptors, and responsiveness to catecholamines. J Clin Invest 1984;73:1473-1482.
32. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.
33. O'Rourke RA, Crawford MH. Mitral valve regurgitation. Curr Probl Cardiol 1984;9:1-52.
34. Dogterom P, Zbinden G, Reznik GK. Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: An overview. Crit Rev Toxicol 1992;22:203-241,
35. Lefebvre HP, Toutain PL. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Ther 2004;27:265-281.